Spots Global Cancer Trial Database for esophageal squamous cell carcinoma (escc)
Every month we try and update this database with for esophageal squamous cell carcinoma (escc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | NCT04210115 | Esophageal Squa... Gastroesophagea... Esophageal Aden... | pembrolizumab placebo cisplatin 5-FU radiotherapy leucovorin levoleucovorin oxaliplatin | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | NCT03430843 | Esophageal Squa... | Tislelizumab Paclitaxel Docetaxel Irinotecan | 18 Years - | BeiGene | |
| A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | NCT03430843 | Esophageal Squa... | Tislelizumab Paclitaxel Docetaxel Irinotecan | 18 Years - | BeiGene | |
| A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | NCT03783442 | Esophageal Squa... | Cisplatin Oxaliplatin Fluorouracil (5... Capecitabine Paclitaxel Tislelizumab Placebo | 18 Years - | BeiGene | |
| A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | NCT04704154 | Solid Tumors | Regorafenib, (S... Nivolumab (Opdi... | 18 Years - | Bayer | |
| A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | NCT03708328 | Solid Tumors Metastatic Mela... Non-small Cell ... Small Cell Lung... Esophageal Squa... | Lomvastomig | 18 Years - | Hoffmann-La Roche | |
| BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study) | NCT04839471 | Esophageal Squa... | BI-754091 plus ... | 20 Years - | National Health Research Institutes, Taiwan | |
| A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies | NCT05473156 | Locally Advance... Non Small Cell ... Head and Neck S... Esophageal Squa... | AP203 AP203 | 18 Years - | AP Biosciences Inc. | |
| IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC) | NCT06078657 | Esophageal Squa... PD-1 Inhibitors | IBI110+Sintilim... | 18 Years - 75 Years | The First Affiliated Hospital of Zhengzhou University | |
| A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | NCT04704154 | Solid Tumors | Regorafenib, (S... Nivolumab (Opdi... | 18 Years - | Bayer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
